SEC Filings

DEF 14A
XTANT MEDICAL HOLDINGS, INC. filed this Form DEF 14A on 12/08/2017
Entire Document
 

 

  

(1)Key assumptions used to estimate the grant date fair value of restricted stock and option awards are contained in Note 10 to the financial statements in our 2016 Annual Report on Form 10-K.

 

(2)Signing bonus.

 

(3)Consulting fees paid to Mr. Di Silvio for services.

 

(4)Effective January 21, 2017, Daniel Goldberger resigned as Chief Executive Officer and a director of the Company.

 

(5)Effective January 21, 2017 Carl O’Connell was appointed as Interim Chief Executive Officer of the Company.  Effective February 17, 2017, Mr. O’Connell was appointed Chief Executive Officer and a director of the Company after serving as Interim Chief Executive Officer since January 21, 2017, and the President of the Company since October 6, 2016.  See Note 18 to the financial statements in our 2016 Annual Report on Form 10-K.

 

(6)Effective August 25, 2017, John Gandolfo resigned as Chief Financial Officer of the Company.

  

The following table shows information about Outstanding Equity Awards to our Named Executive Officers as of December 31, 2016.

 

    Option Awards   Stock Awards  
    Number of 
Securities 
Underlying
Unexercised 
Options
    Equity Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
    Option
Exercise
    Option
Expiration
  Number of
shares or
units
of stock
that
have not
    Market
value of
shares or
units of
stock that
have
 
Name   Exercisable     Options     Price     Date   vested     not vested  
Daniel Goldberger     99,994       100,006     $ 6.00     8/14/23     -       -  
                                             
Carl O’Connell      300,000       300,000       1.11     10/6/26     -       -  
                                             
John Gandolfo       21,500       8,500       5.01     9/4/24     -       -  
      7,000       -       6.80     5/24/23     -       -  

 

Retirement Plans

 

The Company combined the previous two plans for Bacterin and X-spine in 2017. Under the combined plan, the employee becomes qualified after starting employment. Terms for the plan are as follows:

 

Discretionary Match:   3%
     
Contribution Limit:   $18,000 or the statutorily prescribed limit
     
Enrollment Period:   Begins at time of employment

 

Potential Payments Upon Termination or Change-in-Control

 

All of our Named Executive Officers have employment agreements that provide for severance payments for termination in connection with a change in control.

 

18